We also hypothesized that treatment with a PDE4 inhibitor alone would augment any endogenous cAMP production from autocrine/paracrine sources and thereby be sufficient by itself to promote dedifferentiation of SSc MFs in culture. The gene discussed is PDE4A; the disease is systemic sclerosis.